Work

PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: An open-label, non-randomized, phase IV study.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.e16173

Authors: Wenwen Zhang, Shichun Lu, Bingyang Hu, Tao Wan, Hongguang Wang, Jun Han, Ze Zhang, Junning Cao, Xianlei Xin, Yingwei Pan, Minggen HU, Mingyi Chen, Yongliang Chen, Zhanyu Yang, Shouwang Cai, Wenbin Ji, Chenggang Li, Shuang Tong, Feilong Zhao, Xiaochen Zhao

Institutions: Chinese PLA General Hospital, Chinese People's Liberation Army, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, 3D Medicines, Inc. (China)

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3166190928

Cites:

Cited by: 12

Related to: 10